The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Open accessAbstract
CRISPR RNA-guided nucleases (RGNs) are widely used genome-editing reagents, but methods to delineate their genome-wide, off-target cleavage activities have been lacking. Here we describe an approach for global detection of DNA double-stranded breaks (DSBs) introduced by RGNs and potentially other nucleases. This method, called genome-wide, unbiased identification of DSBs enabled by sequencing (GUIDE-seq), relies on capture of double-stranded oligodeoxynucleotides into DSBs. Application of GUIDE-seq to 13 RGNs in two human cell lines revealed wide variability in RGN off-target activities and unappreciated characteristics of off-target sequences. The majority of identified sites were not detected by existing computational methods or chromatin immunoprecipitation sequencing (ChIP-seq). GUIDE-seq also identified RGN-independent genomic breakpoint 'hotspots'. Finally, GUIDE-seq revealed that truncated guide RNAs exhibit substantially reduced RGN-induced, off-target DSBs. Our experiments define the most rigorous framework for genome-wide identification of RGN off-target effects to date and provide a method for evaluating the safety of these nucleases before clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A primary limitation of GUIDE-seq is relevant to the low delivery efficiency of dsODNs into cells, which results in detection of only 30%–50% of all the DSBs (Tsai et al., 2015; Pan et al., 2022).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Off-target profiling of AsCas12a-crRNA+11 genome editing in HEK293/3272-26A>G cells18,42 showed very high specificity, as demonstrated by exclusive editing of the 3272-26A>G CFTR locus, while non-specific cleavages in the second allele, or any other genomic loci, could not be detected (Fig. 2c and Supplementary Fig. 4c).”
From Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing (2019) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“While cleavage at sites with perfect complementarity to the protospacer domain of the gRNA typically occurs with highest efficiency, cleavage at sites having one to several bases of mismatch with the gRNA can occur. These undesired cleavage events are called “off-target effects” (OTEs)10, and their existence should be minimized for therapeutic applications of genome editing technologies.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The GUIDE-seq procedure10 can be used to empirically identify real off-target sites in cells.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“GUIDE-seq can detect off-target sites with indel frequencies as low as 0.03% (Tsai et al., 2015).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“GUIDE-seq is more sensitive than the IDLV method because dsODNs integrate more efficiently and precisely into DSBs, while the integration events of IDLV is low in number and can distribute as far as 500bp away from the actual DSB sites (Tsai et al., 2015; Cromer et al., 2023).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“However, other publications observed a much lower validation rate (Cencic et al., 2014; Duan et al., 2014; Tsai et al., 2015).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“These studies indicated that Cas9 could associate with genomic loci without exerting its nuclease function, deposing a major caveat in Cas9 ChIP-Seq-based off-target detection assay.”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, compared to cell-based methods such as GUIDE-seq (see next section) (Tsai et al., 2015), Extru-seq exhibited much lower false negative rate (2.3% versus 29%) (Kwon et al., 2023).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
In the citing paper
“Using the standard Guide-seq protocol, we detected only the Fah target site and one off-target site (defined as Guide-seq off-target site 1, or GOT1) (Supplementary Data Set 1).”
From Adenine base editing in an adult mouse model of tyrosinaemia (2019) · cites this paper as [23]
In the citing paper
“However, silicon methods can only identify part of the off-target cleavage.48”
From CRISPR-Cas9: a new and promising player in gene therapy (2015) · cites this paper as [48]
In the citing paper
“The major barrier of clinical use of CRISPR/Cas9 is its off-target effects [81,82,83].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citationCRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Self-citationRNA-guided editing of bacterial genomes using CRISPR-Cas systems
Jiang, W., Bikard, D., Cox, D., Zhang, F., & Marraffini, L. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2508 · Cited by 2,429
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,009
A chemical-inducible CRISPR–Cas9 system for rapid control of genome editing
Liu, K. I., Ramli, M. N., Woo, A., Wang, Y., Zhao, T., Zhang, X., Yim, D., Chong, B. Y., Ali, G., Chua, M. Z. H., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2179 · Cited by 199
First report of CRISPR/cas9 mediated dna-free editing of 4cl and rve7 genes in chickpea protoplasts
Badhan, S., Ball, A. S., & Mantri, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010396 · Cited by 193
Dixit, S., Kumar, A., Srinivasan, K., Vincent, P. M. D. R., & Krishnan, N. R. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1335901 · Cited by 193
Delivery and Specificity of CRISPR/Cas9 Genome Editing Technologies for Human Gene Therapy
Gori, J. L., Hsu, P. D., Maeder, M. L., Shen, S., Welstead, G. G., & Bumcrot, D. A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.074 · Cited by 200
Genome-wide target specificity of CRISPR RNA-guided adenine base editors
Kim, D., Kim, D.-E., Lee, G., Cho, S.-I., & Kim, J. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0050-1 · Cited by 192
Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss
György, B., Nist-Lund, C. A., Pan, B., Asai, Y., Karavitaki, K. D., Kleinstiver, B. P., Garcia, S. P., Zaborowski, M. P., Solanes, P., Spataro, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0500-9 · Cited by 196
Self-citationBase editors for simultaneous introduction of C-to-T and A-to-G mutations
Sakata, R. C., Ishiguro, S., Mori, H., Tanaka, M., Tatsuno, K., Ueda, H., Yamamoto, S., Seki, M., Masuyama, N., Nishida, K., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0509-0 · Cited by 197
Genome Editing in Plants: Exploration of Technological Advancements and Challenges
Vats, S., Kumawat, S., Kumar, V., Patil, G., Joshi, T., Sonah, H., Sharma, T. R., & Deshmukh, R. K. (2019) · Cells · doi:10.3390/cells8111386 · Cited by 195
CRISPaint allows modular base-specific gene tagging using a ligase-4-dependent mechanism
Schmid-Burgk, J. L., Höning, K., Ebert, T. S., & Hornung, V. (2016) · Nature Communications · doi:10.1038/ncomms12338 · Cited by 197
Yu, Y., Leete, T., Born, D. A., Young, L., Barrera, L. A., Lee, S., Rees, H. A., Ciaramella, G., & Gaudelli, N. M. (2020) · Nature Communications · doi:10.1038/s41467-020-15887-5 · Cited by 195
Höijer, I., Emmanouilidou, A., Östlund, R., van Schendel, R., Bozorgpana, S., Tijsterman, M., Feuk, L., Gyllensten, U. B., den Hoed, M., & Ameur, A. (2022) · Nature Communications · doi:10.1038/s41467-022-28244-5 · Cited by 205
Smith, J., Suresh, S., Schlecht, U., Wu, M., Wagih, O., Peltz, G., Davis, R. W., Steinmetz, L. M., Parts, L., & St.Onge, R. P. (2016) · Genome biology · doi:10.1186/s13059-016-0900-9 · Cited by 199
Smith, I. C. P., Greenside, P., Natoli, T. E., Lahr, D. L., Wadden, D., Tirosh, I., Narayan, R., Root, D. E., Golub, T. R., Subramanian, A., et al. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2003213 · Cited by 197
The road ahead in genetics and genomics
McGuire, A. L., Gabriel, S., Tishkoff, S. A., Wonkam, A., Chakravarti, A., Furlong, E. E. M., Treutlein, B., Meissner, A., Chang, H. Y., López-Bigas, N., et al. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0272-6 · Cited by 188
Gene correction for SCID-X1 in long-term hematopoietic stem cells
Pavel-Dinu, M., Wiebking, V., Dejene, B. T., Srifa, W., Mantri, S., Nicolas, C. E., Lee, C. M., Bao, G., Kildebeck, E., Punjya, N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09614-y · Cited by 193
CRISPR/Cas9 genome editing technology in filamentous fungi: progress and perspective
Song, R., Zhai, Q., Sun, L., Huang, E., Zhang, Y., Zhu, Y., Guo, Q., Tian, Y., Zhao, B., & Lu, H. X. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10007-w · Cited by 194
Consumer acceptance of food crops developed by genome editing
Ishii, T., & Araki, M. (2016) · Plant Cell Reports · doi:10.1007/s00299-016-1974-2 · Cited by 186
CRISPR/Cas9 Immune System as a Tool for Genome Engineering
Hryhorowicz, M., Lipiński, D., Zeyland, J., & Słomski, R. (2016) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0427-5 · Cited by 206
In vivo genome editing improves motor function and extends survival in a mouse model of ALS
Gaj, T., Ojala, D. S., Ekman, F. K., Byrne, L. C., Limsirichai, P., & Schaffer, D. V. (2017) · Science Advances · doi:10.1126/sciadv.aar3952 · Cited by 185
“DSBs induced by Cas9 enable the introduction of frameshift-inducing base insertions and/ or deletions (indels) that can disrupt gene expression following DNA repair (22).”
BackgroundOff-target predictions in CRISPR-Cas9 gene editing using deep learning
Lin, J., & Wong, K.-C. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty554 · Cited by 185
Development of CRISPR-Cas systems for genome editing and beyond
Zhang, F. (2019) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583519000052 · Cited by 188
Accurate genomic variant detection in single cells with primary template-directed amplification
Gonzalez-Pena, V., Natarajan, S., Xia, Y., Klein, D., Carter, R., Pang, Y., Shaner, B., Annu, K., Putnam, D. K., Chen, W., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024176118 · Cited by 188
Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics
Liu, W., Li, L., Jiang, J., Wu, M., & Lin, P. (2021) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbab014 · Cited by 196
Synthetic CRISPR RNA-Cas9–guided genome editing in human cells
Rahdar, M., McMahon, M. A., Prakash, T. P., Swayze, E. E., Bennett, C. F., & Cleveland, D. W. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520883112 · Cited by 184
Ling, S., Yang, S., Hu, X., Yin, D., Dai, Y., Qian, X., Wang, D., Pan, X., Hong, J., Sun, X., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00656-y · Cited by 187
Precision genome editing using cytosine and adenine base editors in mammalian cells
Huang, T. P., Newby, G. A., & Liu, D. R. (2021) · Nature Protocols · doi:10.1038/s41596-020-00450-9 · Cited by 175
Dual-AAV delivering split prime editor system for in vivo genome editing
Zhi, S., Chen, Y., Wu, G., Wen, J., Wu, J., Liu, Q., Li, Y., Kang, R., Hu, S., Wang, J., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2021.07.011 · Cited by 174
Deciphering, Communicating, and Engineering the CRISPR PAM
Leenay, R. T., & Beisel, C. L. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.11.024 · Cited by 180
Evaluating and enhancing target specificity of gene-editing nucleases and deaminases
Kim, D., Luk, K., Wolfe, S. A., & Kim, J.-S. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111730 · Cited by 171
CRISPR-Cas9 off-targeting assessment with nucleic acid duplex energy parameters
Alkan, F., Wenzel, A., Anthon, C., Havgaard, J. H., & Gorodkin, J. (2018) · Genome biology · doi:10.1186/s13059-018-1534-x · Cited by 174
Lattanzi, A., Camarena, J., Lahiri, P., Segal, H., Srifa, W., Vakulskas, C. A., Frock, R. L., Kenrick, J., Lee, C. M., Talbott, N., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf2444 · Cited by 171
CRISPR-Cas9D10A nickase-based genotypic and phenotypic screening to enhance genome editing
Chiang, T.-W. W., le Sage, C., Larrieu, D., Demir, M., & Jackson, S. P. (2016) · Scientific Reports · doi:10.1038/srep24356 · Cited by 171
R-loop formation and conformational activation mechanisms of Cas9
Pačesa, M., Loeff, L., Querques, I., Muckenfuss, L. M., Sawicka, M., & Jínek, M. (2022) · Nature · doi:10.1038/s41586-022-05114-0 · Cited by 176
Zuo, E., Sun, Y., Yuan, T., He, B., Zhou, C., Ying, W., Liu, J., Wu, W., Zeng, R., Li, Y., et al. (2020) · Nature Methods · doi:10.1038/s41592-020-0832-x · Cited by 166
Zhang, Y., Yin, C., Zhang, T., Li, F., Yang, W., Kaminski, R., Fagan, P. R., Putatunda, R., Young, W., Khalili, K., et al. (2015) · Scientific Reports · doi:10.1038/srep16277 · Cited by 174
Ekman, F. K., Ojala, D. S., Adil, M. M., Zapana, P. A. L., Schaffer, D. V., & Gaj, T. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.07.009 · Cited by 165
CRISPR/Cas9-mediated genome editing and gene replacement in plants: Transitioning from lab to field
Schaeffer, S. M., & Nakata, P. A. (2015) · Plant Science · doi:10.1016/j.plantsci.2015.09.011 · Cited by 166
Lau, C.-H., & Suh, Y. (2017) · F1000Research · doi:10.12688/f1000research.11243.1 · Cited by 161
AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines
Zhang, L., Zuris, J. A., Viswanathan, R., Edelstein, J., Turk, R., Thommandru, B., Rube, H. T., Glenn, S. E., Collingwood, M. A., Bode, N. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24017-8 · Cited by 170
Ozseyhan, M. E., Kang, J., Mu, X., & Lu, C. (2017) · Plant Physiology and Biochemistry · doi:10.1016/j.plaphy.2017.11.021 · Cited by 160
Patterns of CRISPR/Cas9 activity in plants, animals and microbes
Bortesi, L., Zhu, C., Zischewski, J., Pérez, L., Bassié, L., Nadi, R., Forni, G., Lade, S. B., Soto, E., Jin, X., et al. (2016) · Plant Biotechnology Journal · doi:10.1111/pbi.12634 · Cited by 167
CRISPR interference-based specific and efficient gene inactivation in the brain
Zheng, Y., Shen, W., Zhang, J., Yang, B., Liu, Y., Qi, H., Yu, X., Lu, S., Chen, Y., Xu, Y., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0077-5 · Cited by 162
DSBCapture: in situ capture and sequencing of DNA breaks
Lensing, S. V., Marsico, G., Hänsel‐Hertsch, R., Lam, E. Y. N., Tannahill, D., & Balasubramanian, S. (2016) · Nature Methods · doi:10.1038/nmeth.3960 · Cited by 155
Wang, X., Hu, L., Hao, J., Liao, L., Chiu, Y.-T., Shi, M., & Wang, Y. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0292-7 · Cited by 155
Unbiased investigation of specificities of prime editing systems in human cells
Kim, D. Y., Moon, S. B., Ko, J., Kim, Y.-S., & Kim, D. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa764 · Cited by 162
Systematic analysis of CRISPR–Cas9 mismatch tolerance reveals low levels of off-target activity
Anderson, E. M., Haupt, A., Schiel, J. A., Chou, E. T., Machado, H. B., Strezoska, Ž., Lenger, S., McClelland, S., Birmingham, A., Vermeulen, A., et al. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.06.427 · Cited by 154
Merkle, F. T., Neuhausser, W. M., Santos, D., Valen, E., Gagnon, J. A., Maas, K., Sandoe, J., Schier, A. F., & Eggan, K. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.007 · Cited by 152
FlashFry: A fast and flexible tool for large-scale CRISPR target design
McKenna, A., & Shendure, J. (2018) · BMC Biology · doi:10.1186/s12915-018-0545-0 · Cited by 152
Kouranova, E. V., Forbes, K. P., Zhao, G., Warren, J., Bartels, A., Wu, Y., & Cui, X. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.009 · Cited by 151
CRISPR-Cas12a has widespread off-target and dsDNA-nicking effects
Murugan, K., Seetharam, A. S., Severin, A. J., & Sashital, D. G. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012933 · Cited by 153
Characteristics of Genome Editing Mutations in Cereal Crops
Zhu, C., Bortesi, L., Baysal, C., Twyman, R. M., Fischer, R., Capell, T., Schillberg, S., & Christou, P. (2016) · Trends in Plant Science · doi:10.1016/j.tplants.2016.08.009 · Cited by 149
Enhancement of target specificity of CRISPR–Cas12a by using a chimeric DNA–RNA guide
Kim, H., Lee, W.-J., Oh, Y., Kang, S.-H., Hur, J. K., Lee, H., Song, W., Lim, K. S., Park, Y., Song, B., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa605 · Cited by 151
Genome-wide profiling of adenine base editor specificity by EndoV-seq
Liang, P., Xie, X., Zhi, S., Sun, H., Zhang, X., Chen, Y., Chen, Y., Xiong, Y., Ma, W., Liu, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07988-z · Cited by 148
Park, S. H., Lee, C. M., Dever, D. P., Davis, T., Camarena, J., Srifa, W., Zhang, Y., Paikari, A., Chang, A. K., Porteus, M. H., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz475 · Cited by 152
Tóth, E., Varga, É., Kulcsár, P. I., Kocsis-Jutka, V., Krausz, S. L., Nyeste, A., Welker, Z., Huszár, K., Ligeti, Z., Tálas, A., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa110 · Cited by 147
CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo—Brief Report
Wang, X., Raghavan, A., Chen, T., Qiao, L., Zhang, Y., Ding, Q., & Musunuru, K. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307227 · Cited by 146
Immunity to CRISPR Cas9 and Cas12a therapeutics
Chew, W. L. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1408 · Cited by 150
Kim, H. K., Lee, S., Kim, Y., Park, J., Min, S., Choi, J. W., Huang, T. P., Yoon, S., Liu, D. R., & Kim, H. H. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0505-1 · Cited by 145
Burnight, E. R., Gupta, M., Wiley, L. A., Anfinson, K. R., Tran, A. A., Triboulet, R., Hoffmann, J. M., Klaahsen, D., Andorf, J. L., Jiao, C., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.015 · Cited by 153
Mitigation of off-target toxicity in CRISPR-Cas9 screens for essential non-coding elements
Tycko, J., Wainberg, M., Marinov, G. K., Ursu, O., Hess, G. T., Ego, B. K., Aradhana, Li, A., Truong, A., Trevino, A. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11955-7 · Cited by 150
Gasperini, M., Findlay, G. M., McKenna, A., Milbank, J. H., Lee, C., Zhang, M. D., Cusanovich, D. A., & Shendure, J. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.06.010 · Cited by 143
Wyvekens, N., Topkar, V. V., Khayter, C., Joung, J. K., & Tsai, S. Q. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.084 · Cited by 147
Self-citationThe influence of eukaryotic chromatin state on CRISPR–Cas9 editing efficiencies
Verkuijl, S. A. N., & Rots, M. G. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.07.005 · Cited by 151
A compact Cas9 ortholog from Staphylococcus Auricularis (SauriCas9) expands the DNA targeting scope
Hu, Z., Wang, S., Zhang, C., Gao, N., Li, M., Wang, D., Wang, D., Liu, D., Liu, H., Ong, S., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000686 · Cited by 144
Next-generation cell therapies: the emerging role of CAR-NK cells
Başar, R., Daher, M., & Rezvani, K. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002547 · Cited by 145
Weber, L., Frati, G., Felix, T., Hardouin, G., Casini, A., Wollenschlaeger, C., Meneghini, V., Masson, C., De Cian, A., Chalumeau, A., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay9392 · Cited by 140
α-Globin as a molecular target in the treatment of β-thalassemia
Mettananda, S., Gibbons, R. J., & Higgs, D. R. (2015) · Blood · doi:10.1182/blood-2015-03-633594 · Cited by 144
Josephs, E. A., Koçak, D. D., Fitzgibbon, C. J., McMenemy, J., Gersbach, C. A., & Marszałek, P. E. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv892 · Cited by 147
A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy
Srivas, R., Shen, J. P., Yang, C. C., Sun, S. M., Li, J., Gross, A. M., Jensen, J., Licon, K., Bojorquez-Gomez, A., Klepper, K., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.022 · Cited by 143
The chemistry of Cas9 and its CRISPR colleagues
Chen, J. S., & Doudna, J. A. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0078 · Cited by 143
Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome
Kuo, C. Y., Long, J. D., Campo-Fernández, B., Oliveira, S. N. D., Cooper, A. R., Romero, Z. G., Hoban, M. D., Joglekar, A. V., Lill, G. R., Kaufman, M. L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.103 · Cited by 138
Improved cytosine base editors generated from TadA variants
Lam, D. K., Feliciano, P. R., Arif, A., Bohnuud, T., Fernandez, T. P., Gehrke, J. M., Grayson, P., Lee, K. D., Ortega, M. A., Sawyer, C. B., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01611-9 · Cited by 140
CRISPR-Cas in Streptococcus pyogenes
Rhun, A. L., Escalera-Maurer, A., Bratovič, M., & Charpentier, E. (2019) · RNA Biology · doi:10.1080/15476286.2019.1582974 · Cited by 143
Chang, K. S., Kim, J., Park, H., Hong, S.-J., Lee, C., & Jin, E. (2020) · Bioresource Technology · doi:10.1016/j.biortech.2020.122932 · Cited by 137
An Outlook on Global Regulatory Landscape for Genome-Edited Crops
Ahmad, A., Munawar, N., Khan, Z., Qumsani, A. T., Khan, S. H., Jamil, A., Ashraf, S., Ghouri, M. Z., Aslam, S., Mubarik, M. S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111753 · Cited by 140
Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic Effects
Georgiadis, C., Preece, R., Nickolay, L. E., Etuk, A., Petrova, A., Ładoń, D., Danyi, A., Humphryes-Kirilov, N., Ajetunmobi, A., Kim, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.025 · Cited by 140
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
Prakash, V., Moore, M., & Yáñez‐Muñoz, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.5 · Cited by 138
Wimberger, S., Akrap, N., Firth, M. A., Brengdahl, J., Engberg, S., Schwinn, M. K., Slater, M. R., Lundin, A., Hsieh, P.-P., Li, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40344-4 · Cited by 140
DNA stretching induces Cas9 off-target activity
Newton, M. D., Taylor, B., Driessen, R. P. C., Roos, L., Cvetešić, N., Allyjaun, S., Lenhard, B., Cuomo, M. E., & Rueda, D. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0188-z · Cited by 142
Genome Editing in Cereals: Approaches, Applications and Challenges
Ansari, W. A., Chandanshive, S. U., Bhatt, V. D., Nadaf, A. B., Vats, S., Katara, J. L., Sonah, H., & Deshmukh, R. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114040 · Cited by 138
Ferrari, S., Jacob, A., Cesana, D., Laugel, M., Beretta, S., Varesi, A., Unali, G., Conti, A., Canarutto, D., Albano, L., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.09.001 · Cited by 133
Zhang, D., Zhang, H., Li, T., Chen, K., Qiu, J., & Gao, C. (2017) · Genome biology · doi:10.1186/s13059-017-1325-9 · Cited by 133
Recent Advances in Genome Editing Using CRISPR/Cas9
Ding, Y., Li, H., Chen, L., & Xie, K. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00703 · Cited by 144
UDiTaS™, a genome editing detection method for indels and genome rearrangements
Giannoukos, G., Ciulla, D., Marco, E., Abdulkerim, H. S., Barrera, L. A., Bothmer, A., Dhanapal, V., Gloskowski, S. W., Jayaram, H., Maeder, M. L., et al. (2018) · BMC Genomics · doi:10.1186/s12864-018-4561-9 · Cited by 131
Computational Tools and Resources for CRISPR/Cas Genome Editing
Li, C., Chu, W., Gill, R. A., Sang, S., Shi, Y., Hu, X., Yang, Y., Zaman, Q. U., & Zhang, B. (2022) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.02.006 · Cited by 134
Hino, T., Omura, S. N., Nakagawa, R., Togashi, T., Takeda, S. N., Hiramoto, T., Tasaka, S., Hirano, H., Tokuyama, T., Uosaki, H., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.031 · Cited by 131
CRISPR/Cas9‐mediated genome editing: From basic research to translational medicine
Jacinto, F. V., Link, W., & Ferreira, B. I. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14916 · Cited by 135
Rai, R., Romito, M., Rivers, E., Turchiano, G., Blattner, G., Vetharoy, W., Ładoń, D., Andrieux, G., Zhang, F., Zinicola, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17626-2 · Cited by 134
Chu, V. T., Graf, R., Wirtz, T., Weber, T., Favret, J., Li, X., Petsch, K., Tran, N. T., Sieweke, M. H., Berek, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613884113 · Cited by 129
Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage
Kulcsár, P. I., Tálas, A., Huszár, K., Ligeti, Z., Tóth, E., Weinhardt, N., Fodor, E., & Welker, E. (2017) · Genome biology · doi:10.1186/s13059-017-1318-8 · Cited by 134
CRISPR-UMI: single-cell lineage tracing of pooled CRISPR–Cas9 screens
Michlits, G., Hubmann, M., Wu, S.-H. S., Vainorius, G., Budusan, E., Zhuk, S., Burkard, T. R., Novatchkova, M., Aichinger, M., Lü, Y., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4466 · Cited by 131
Giannelli, S. G., Luoni, M., Castoldi, V., Massimino, L., Cabassi, T., Angeloni, D., Demontis, G. C., Leocani, L., Andreazzoli, M., & Broccoli, V. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx438 · Cited by 133
Diversifying the structure of zinc finger nucleases for high-precision genome editing
Paschon, D. E., Lussier, S. J., Wangzor, T., Xia, D. F., Li, P. W., Hinkley, S. J., Scarlott, N. A., Lam, S. C., Waite, A. J., Truong, L. N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08867-x · Cited by 131
An engineered ScCas9 with broad PAM range and high specificity and activity
Chatterjee, P., Jakimo, N., Lee, J., Amrani, N., Rodríguez, T., Koseki, S., Tysinger, E., Qing, R., Hao, S., Sontheimer, E. J., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0517-0 · Cited by 131
Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells
Mungenast, A. E., Siegert, S., & Tsai, L. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.11.010 · Cited by 136
In Silico Meets In Vivo : Towards Computational CRISPR-Based sgRNA Design
Chuai, G., Wang, Q., & Liu, Q. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2016.06.008 · Cited by 134
Implications of human genetic variation in CRISPR-based therapeutic genome editing
Scott, D. A., & Zhang, F. (2017) · Nature Medicine · doi:10.1038/nm.4377 · Cited by 129
Genome-wide specificity of prime editors in plants
Jin, S., Lin, Q., Luo, Y., Zhu, Z., Liu, G., Li, Y., Chen, K., Qiu, J., & Gao, C. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00891-x · Cited by 131
Barriers for HIV Cure: The Latent Reservoir
Castro‐Gonzalez, S., Colomer-Lluch, M., & Serra-Moreno, R. (2018) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2018.0118 · Cited by 134
Massively parallel kinetic profiling of natural and engineered CRISPR nucleases
Jones, S. K., Hawkins, J. A., Johnson, N. V., Jung, C., Hu, K., Rybarski, J. R., Chen, J. S., Doudna, J. A., Press, W. H., & Finkelstein, I. J. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0646-5 · Cited by 131
Metadata
- Authors
- Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., Aryee, M. J., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Tsai, Shengdar Q
- Joung, J Keith
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2014-12-16
- Volume
- 33
- Issue
- 2
- Pages
- 187-197
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4320685
- OpenAlex
- W2003797386
- Cited by
- 2,268
- References
- 39
- Citations by year
- 2026: 189 · 2025: 211 · 2024: 196 · 2023: 191 · 2022: 208 · 2021: 211 · 2020: 231 · 2019: 186 · 2018: 187 · 2017: 177 · 2016: 172 · 2015: 105 · 2014: 1
- FWCI
- 62.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM088040, F32GM105189)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR063070)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- GUIDE-seq, CRISPR-Cas nucleases, off-target cleavage, DNA double-strand breaks, genome-wide characterization, genome editing safety
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Cell Line, Humans, Oligodeoxyribonucleotides, Genome, Human, RNA Editing, DNA Breaks, Double-Stranded, High-Throughput Nucleotide Sequencing, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
